Skip to content
Triangle logo TriangleGet started
← Study library

NCT00112827 · REGISTRY CONDITION SEARCH

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
COMPLETED
Registry last update
2025-06-06

RATIONALE: Melphalan, a chemotherapeutic agent, has been found to be an effective treatment choice for destroying myeloma cells, especially when given at high (bone marrow ablative) doses. Total marrow irradiation (TMI)/ablative dose radiation therapy is another modality capable of destroying myeloma cells. Autologous peripheral blood/stem cell transplant (ASCT) given after either melphalan or following TMI (aimed at the bone marrow containing areas of the skeleton, the site of origin of myeloma cells) will shorten the duration/alleviate the severity of both melphalan and marrow irradiation-associated side effects. Lenalidomide, an effective agent on its own right for the treatment of myeloma, has been shown to further enhance the beneficial effects of autologous stem cell transplants when given as maintenance therapy. PURPOSE: This previously phase I trial established the maximum tolerated dose of TMI at 1600 cGy. The phase II part of this study is ongoing and is studying the effects of high-dose melphalan and ASCT, followed by TMI and a second ASCT, with subsequent maintenance lenalidomide. The study is conducted in patients with stages I-III myeloma, with specific emphasis on assessing complete and very good partial response rate conversions, progression-free and overall survival, and safety/feasibility of delivering the planned treatment regimen.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Maximum Tolerated Dose (MTD)

→

outcome · POSTED

Number of Subjects With Response

→

outcome · POSTED

Overall Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Criteria * Patients with multiple myeloma (stages I-III) will be eligible if they are either in response, or have stable disease * Patients with smoldering myeloma are eligible if there is evidence of progressive disease requiring therapy (\>= 25% increase in M protein levels or Bence Jones excretion; Hgb =\< 10.5 g/dl; frequent infections; hypercalcemia; rise in serum creatinine above normal on two separate occasion) * Patients with non-quantifiable monoclonal proteins are eligible provided they meet other criteria for multiple myeloma, or smoldering myeloma, and they have evaluable or measurable disease by other (radiographic) means * Unlimited prior chemotherapy regimens allowed * KPS \>= 70% * Patients with Waldenstrom's macroglobulinemia are not eligible * Less than 18 months since diagnosis * No contraindication to the collection of a minimum of 4 x 10\^6 CD34+ cells/kg by apheresis * All patients must have signed a voluntary, informed consent in accordance with institutional and federal guidelines * Adequate hepatic function as demonstrated by bilirubin, =\< 1.5 mg/dl, and SGOT and SGPT \< 2.5 x upper limits of normal * Adequate renal function as demonstrated by: creatinine of measured or calculated creatinine clearance of \> 50 cc/min * Absolute neutrophil count of \> 1000/ul, platelet count of \> 100,000/ul * Cardiac ejection fraction \>= 50% by MUGA scan and/or by echocardiogram * Adequate pulmonary function as demonstrated by FEV1 \> 60% and DLCO \> 50% of predicted lower limit * Hepatitis B antigen, Hepatitis C RNA and HIV antibody tests negative * No other medical, or psychosocial problems, which in the opinion of the primary physician or principal investigator would place the patient at unacceptably high risk from this treatment regimen * Females of reproductive age not using adequate birth control measures/ or who are pregnant are not eligible * History of other malignancies within the last 3 years, as long as patients have remained in complete remission for at least 2 years, except for non-melanoma skin cancer and in situ carcinoma of the cervix * Patients should have finished their prior chemotherapy at least 14 days prior to cyclophosphamide priming, and should have received their last dose of thalidomide, dexamethasone, or bisphosphonate \> 10 days prior to cyclophosphamide priming * Pre-treatment tests must have been performed within 6 weeks prior to initiation of cyclophosphamide; A CBC, platelet count and comprehensive chemistry panel should be performed within 1 week prior to initiating cyclophosphamide priming * Known hypersensitivity to Filgrastim or to E. coli derived proteins is an exclusion * Inability to lie supine in a full body cast for approximately 30 minutes, the anticipated duration of each treatment session, is an exclusion * Previous radiation therapy to more than 20% of bone marrow containing areas, or to any area exceeding 2000 cGy, is an exclusion * Patients must be fully aware of the teratogenic potential of thalidomide and agree to fully comply with the mandated guidelines regarding contraception as stated in the informed consent and the patient warning document attached to the consent form * Women of childbearing potential must have a negative pregnancy test performed within 24 hours prior to beginning thalidomide, except for woman who have been postmenopausal for at least 2 years, or underwent hysterectomy * Use of effective means of contraceptive should be started at least 2 weeks prior to initiating thalidomide
healthy Volunteers
false
maximum Age
70 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
  3. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    See Detailed Description
    intervention Names
    1. Radiation: total marrow irradiation
    2. Drug: melphalan
    3. Procedure: peripheral blood stem cell transplantation
    4. Biological: filgrastim
    5. Genetic: fluorescence in situ hybridization
    6. Genetic: cytogenetic analysis
    7. Drug: cyclophosphamide
    8. Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
    9. Drug: lenalidomide
    label
    Arm I
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm I
    description
    Undergo irradiation
    name
    total marrow irradiation
    type
    RADIATION
  2. arm Group Labels
    1. Arm I
    description
    Given IV
    name
    melphalan
    other Names
    1. Alkeran
    2. CB-3025
    3. L-PAM
    4. L-phenylalanine mustard
    5. L-Sarcolysin
    6. Melfalan
    type
    DRUG
  3. arm Group Labels
    1. Arm I
    description
    Undergo transplantation
    name
    peripheral blood stem cell transplantation
    other Names
    1. PBPC transplantation
    2. PBSC transplantation
    3. peripheral blood progenitor cell transplantation
    4. transplantation, peripheral blood stem cell
    type
    PROCEDURE
  4. arm Group Labels
    1. Arm I
    description
    Given IV
    name
    filgrastim
    other Names
    1. G-CSF
    2. granulocyte colony-stimulating factor
    3. Neupogen
    4. r-metHuG-CSF
    5. Recombinant Methionyl Human Granulocyte Colony Stimulating Factor
    type
    BIOLOGICAL
  5. arm Group Labels
    1. Arm I
    description
    Correlative studies
    name
    fluorescence in situ hybridization
    other Names
    1. fluorescence in situ hybridization (FISH)
    type
    GENETIC
  6. arm Group Labels
    1. Arm I
    description
    Correlative studies
    name
    cytogenetic analysis
    type
    GENETIC
  7. arm Group Labels
    1. Arm I
    description
    Given IV
    name
    cyclophosphamide
    other Names
    1. CPM
    2. CTX
    3. Cytoxan
    4. Endoxan
    5. Endoxana
    6. Enduxan
    type
    DRUG
  8. arm Group Labels
    1. Arm I
    description
    Undergo transplantation
    name
    autologous-autologous tandem hematopoietic stem cell transplantation
    type
    PROCEDURE
  9. arm Group Labels
    1. Arm I
    description
    Given orally
    name
    lenalidomide
    other Names
    1. CC-5013
    2. IMiD-1
    3. Revlimid
    type
    DRUG
Study design
allocation
NA
intervention Model
SEQUENTIAL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
54
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    The highest dose tested (Total Marrow Irradiation) in which there is no treatment related mortality and none or only one patient experienced dose limited toxicity (DLT) attributable to the study drug(s), when at least six were fully treated at that dose and fully followed for toxicity. The MTD is one dose level below the lowest dose tested in which 2 or more patients experienced DLT attributable to the treatment or there was a treatment related death. At least 6 patients will be treated at the MTD.
    measure
    Maximum Tolerated Dose (MTD)
    time Frame
    8 weeks from start of treatment, up to 2 years
  2. description
    Response defined as complete response or very good partial response. Complete response defined as the absence of bone marrow or blood findings of multiple myeloma on at least 2 measurements at a minimum of a 6 week interval. Thus all evidence of serum and urinary M-components must disappear on electrophoresis as well as by immunofixation studies. The follow-up bone marrow may not contain more than 5% plasma cells on aspiration or core biopsy and no evidence of increasing anemia. Skeletal X-rays must either show recalcification or no change in osteolytic lesions. Resolution of soft tissue plasmocytomas. Very good partial response defined as reduction of bone marrow or blood findings of multiple myeloma on at least 2 measurements at a minimum of a 6 week interval by greater than or equal to 90%.
    measure
    Number of Subjects With Response
    time Frame
    Evaluated after each course until completion of treatment.
  3. description
    Estimated using the product-limit method of Kaplan and Meier. Event defined as death due to any cause.
    measure
    Overall Survival
    time Frame
    From date of treatment until the date of death from any cause, assessed up to 14 years
Full study description
brief Summary
RATIONALE: Melphalan, a chemotherapeutic agent, has been found to be an effective treatment choice for destroying myeloma cells, especially when given at high (bone marrow ablative) doses. Total marrow irradiation (TMI)/ablative dose radiation therapy is another modality capable of destroying myeloma cells. Autologous peripheral blood/stem cell transplant (ASCT) given after either melphalan or following TMI (aimed at the bone marrow containing areas of the skeleton, the site of origin of myeloma cells) will shorten the duration/alleviate the severity of both melphalan and marrow irradiation-associated side effects. Lenalidomide, an effective agent on its own right for the treatment of myeloma, has been shown to further enhance the beneficial effects of autologous stem cell transplants when given as maintenance therapy. PURPOSE: This previously phase I trial established the maximum tolerated dose of TMI at 1600 cGy. The phase II part of this study is ongoing and is studying the effects of high-dose melphalan and ASCT, followed by TMI and a second ASCT, with subsequent maintenance lenalidomide. The study is conducted in patients with stages I-III myeloma, with specific emphasis on assessing complete and very good partial response rate conversions, progression-free and overall survival, and safety/feasibility of delivering the planned treatment regimen.
detailed Description
PRIMARY OBJECTIVES: I. To assess the feasibility and toxicities of tandem cycle ablative therapy consisting first of high-dose melphalan and then escalating doses of fractionated total marrow irradiation (TMI) using helical tomotherapy in patients with advanced multiple myeloma. II. To establish the maximum tolerated dose of TMI using helical tomotherapy. III. To assess response rate, progression free and over-all survival following treatment with tandem cycle ablative therapy consisting first of high-dose melphalan and then escalating doses of TMI using helical tomotherapy with Dexamethasone/Thalidomide maintenance therapy in patients with advanced multiple myeloma. IV. To assess the feasibility of adding decadron and thalidomide as maintenance following the second cycle of high-dose therapy. SECONDARY OBJECTIVES: I. To perform cytogenetic, gene rearrangement, and fluorescence in situ hybridization (FISH) studies on baseline and post-treatment bone marrow and blood specimens and correlate the presence/persistence of these features with treatment outcome. II. To bank/develop cell lines developed for future investigations of tumor biology, and for potential assessment of efficacy of novel therapeutic agents. OUTLINE: This is a dose-escalation study of total marrow irradiation (TMI). PRIMING AND APHERESIS: Patients receive cyclophosphamide IV over 2 hours. Patients also receive filgrastim IV or subcutaneously daily beginning 24 hours after the administration of cyclophosphamide and continuing until apheresis is complete. Patients undergo apheresis until an adequate number of peripheral blood stem cells are collected. ABLATIVE THERAPY: Course 1: Patients receive high-dose melphalan IV over 30 minutes on days -2 and -1. Patients then undergo autologous PBSC transplantation on day 0 and receive filgrastim IV or subcutaneously beginning on day 5 and continuing until blood counts recover. Course 2: Beginning 6-18 weeks later, patients undergo TMI once or twice daily on days -4 to -1. Patients then undergo autologous peripheral blood stem cell transplant and receive filgrastim IV or subcutaneously beginning on day 5 and continuing until blood counts recover. MAINTENANCE THERAPY: Beginning within 6-8 weeks of day 0 of course 2 (TMI), patients receive oral lenalidomide daily. Courses repeat every 28 days for approximately 3 years in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days, every 6 months for 1 year, and then annually for at least 2 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-38cb9e2f9d3af90be13a
      requested nct id
      NCT00112827
      primary nct id
      NCT00112827
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      756417f1bdf3f300f68ed1f1382f3498b8dd4a122eed23b5e8f796c54924ab3c
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-38cb9e2f9d3af90be13a
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00112827
      occurrences
      1. context exact
        NCT00112827
        end
        11
        exact text
        NCT00112827
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/984/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      8c5417667fd43adf5b6a6b53f0fe27859232fc823a029cb02feb4e37cfc58443

    Preserved source evidence · Not medical advice